More than thirty partners from the EU and the United Kingdom of the ‘Primavera’ project are meeting today and tomorrow at the Macarena campus to measure the progress of the third year of development of this research

The Hospital Universitario Virgen Macarena (HUVM) is hosting today and tomorrow the meeting of the ‘Primavera’ project, coordinated by the European Vaccine Initiative, which aims to take advantage of big data, mathematical models and artificial intelligence to promote the fight against antimicrobial resistance through vaccines and monoclonal antibodies. During these days, the 21 participating institutions, from scientific and academic institutions, and pharmaceutical companies will review the progress in the development of the project in the last year, with two years to go until its closure.

‘Primavera’ has five work packages. The first is responsible for investigating the burden of disease linked to antimicrobial resistance based on aggregate data; the second, for developing mathematical models; the third (coordinated by the Hospital Universitario Virgen Macarena (HUVM), for providing data on the impact of resistance based on individualizable data; the fourth, for the analysis of the cost-effectiveness of the developed model; and the fifth, for the overall coordination of the project.

The final objective of the project is to develop an open source web platform – accessible to the entire scientific community – that combines mathematical models with a microbiological, epidemiological repository and both clinical and economic data, which serves as a reference for making sustainable decisions over time regarding the use of vaccines and monoclonal antibodies.

Hospital Universitario Virgen Macarena (HUVM)
The Hospital Universitario Virgen Macarena (HUVM) is participating in this international project by leading work package 3 through the research group coordinated by the doctors Jesús Rodríguez Baño and Mariana Guedes from the Infectious Diseases Service, the Clinical Research Group on Infectious Diseases at the Instituto de Biomedicina de Sevilla (IBiS), and the Innovation Unit, led by Alberto Moreno.
The project has the collaboration of the Fundación para la Gestión de la Investigación en Salud de Sevilla (FISEVI), an entity that also collaborates with the Infectious Diseases Service of the Hospital Universitario Virgen Macarena (HUVM) in more than a dozen projects and clinical trials, both European and national.